{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:46:18Z","timestamp":1789011978835,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clml.2020.11.001","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T07:25:01Z","timestamp":1604647501000},"page":"e301-e308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic Leukemia Without Down Syndrome: A Retrospective Study in China"],"prefix":"10.1016","volume":"21","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-810X","authenticated-orcid":false,"given":"Leping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.11.001_bib1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2402618","article-title":"Acute megakaryoblastic leukemia: experience of GIMEMA trials","volume":"16","author":"Pagano","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.11.001_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.20951","article-title":"Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children\u2019s Oncology Group","volume":"49","author":"Barnard","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2020.11.001_bib3","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood.V97.12.3727","article-title":"Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution\u2019s experience","volume":"97","author":"Athale","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric none Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"De Rooij","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2020.11.001_bib6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-015-2383-2","article-title":"Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial","volume":"94","author":"Schweitzer","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.11.001_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/leu.2012.223","article-title":"Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children\u2019s Oncology Group Study POG 9421","volume":"27","author":"O\u2019Brien","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.11.001_bib8","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood-2015-02-629204","article-title":"Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study","volume":"126","author":"Inaba","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2007.06971.x","article-title":"Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome","volume":"140","author":"Hama","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.001_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2353\/jmoldx.2009.080132","article-title":"Down syndrome and malignancies: a unique clinical relationship\u2014a paper from the 2008 William Beaumont Hospital symposium on molecular pathology","volume":"11","author":"Xavier","year":"2009","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2020.11.001_bib11","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib12","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2008-11-163501","article-title":"Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome","volume":"113","author":"Malinge","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib13","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1182\/blood-2013-05-503011","article-title":"Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes","volume":"122","author":"Malinge","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2009.07789.x","article-title":"Acute megakaryoblastic leukaemia(AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis","volume":"147","author":"Roy","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.001_bib15","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","article-title":"Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study","volume":"127","author":"de Rooij","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib16","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1200\/JCO.2006.06.5037","article-title":"Less toxicity by optimizing chemotherapy, but not by addition of granulocytecolony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98","volume":"24","author":"Creutzig","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.11.001_bib17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.leu.2403815","article-title":"Acute megakaryoblastic leukemia in children and adolescents, excluding Down\u2019s syndrome: improved outcome with intensified induction treatment","volume":"19","author":"Reinhardt","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.11.001_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML 02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.11.001_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/17474086.2019.1609351","article-title":"Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia","volume":"12","author":"De Marchi","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2020.11.001_bib20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.7326\/0003-4819-103-3-460","article-title":"Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2020.11.001_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.blre.2015.07.005","article-title":"Acute megakaryocytic leukemia: what have we learned","volume":"30","author":"Hahn","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2020.11.001_bib22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.leukres.2008.08.026","article-title":"Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease","volume":"33","author":"Qin","year":"2009","journal-title":"Leukemia Res"},{"key":"10.1016\/j.clml.2020.11.001_bib23","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2011-03-342774","article-title":"Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia","volume":"118","author":"Alford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.11.001_bib24","series-title":"An International System for Human Cytogenetics Nomenclature","year":"2009"},{"key":"10.1016\/j.clml.2020.11.001_bib25","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.clml.2018.12.011","article-title":"Outcome of childhood acute megakaryoblastic leukemia: Children\u2019s Cancer Hospital Egypt 57357 experience","volume":"19","author":"Maarouf","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.11.001_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.critrevonc.2019.04.011","article-title":"The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children","volume":"138","author":"Masetti","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2020.11.001_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/leu.2013.198","article-title":"Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome","volume":"28","author":"Chilton","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.11.001_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/gcc.22177","article-title":"Ploidy and clinical characteristics of childhood acute myeloid leukemia: a NOPHO-AML study","volume":"53","author":"Sandahl","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2020.11.001_bib29","first-page":"153","article-title":"[GATA1-mutation associated leukemia in children with trisomy 21 mosaic.]","volume":"224","author":"Reinhardt","year":"2012","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.clml.2020.11.001_bib30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12185-010-0549-1","article-title":"Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy","volume":"91","author":"Kudo","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.11.001_bib31","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/leu.2015.5","article-title":"High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML","volume":"29","author":"Jo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.11.001_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/bjh.12444","article-title":"High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric AML: a report from the Children\u2019s Oncology Group","volume":"162","author":"Ho","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.001_bib33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14093","article-title":"Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia: results of the NOPHO-AML 2004 study","volume":"174","author":"Tierens","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.001_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01study protocol","volume":"177","author":"Buldini","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.11.001_bib35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/08880018.2017.1414905","article-title":"Acute megakaryoblastic leukemia (excluding down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial","volume":"34","author":"Teyssier","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2020.11.001_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2004-03-1103","article-title":"Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"105","author":"Garderet","year":"2005","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020306145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:35:46Z","timestamp":1730529346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020306145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2152265020306145"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic Leukemia Without Down Syndrome: A Retrospective Study in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}